NCT06028945Completed
Evaluating the Impact of Virtual Reality Exposure Therapy on Epilepsy/Seizure-Specific Interictal Anxiety
Randomized Controlled Trial Evaluating the Impact of Virtual Reality Exposure Therapy on Epilepsy/Seizure-Specific Interictal Anxiety In People With Epilepsy
Source: ClinicalTrials.gov · Last updated 17 Nov 2025
Brief summary (registry, in English)
The purpose of this randomized control trial is to evaluate the impact of Virtual Reality (VR) Exposure Therapy (ET) on people with epilepsy who experience epilepsy/seizure-specific (ES) interictal anxiety. The main questions it aims to answer are: 1. Can virtual reality exposure therapy (VR-ET) help reduce ES-interictal anxiety in this population? 2. Are the study procedures sufficiently simple for participants to follow? Study Design Summary: * Fourteen (14) participants will be randomized into either an Experimental arm (receiving VR-ET) or Control arm * Participants will be expected to have VR-ET twice a day (5 min/session) for up to 10 days * Participants will complete self-reported questionnaires about anxiety, depression, quality life, and avoidance behaviours at baseline (T0), after completing their VR program (T2), and at a one-month follow-up (T3). * Participants will have a short interview with a researcher after completing their VR program (T2) as well as at a one-month follow-up (T3). Researchers will attempt to answer the study questions based on outcome measures taken at various timepoints and qualitative feedback from interviews.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 14 (actual)
- First submitted
- 31 Aug 2023
- Start date
- 24 May 2024
- Primary completion date
- 11 Nov 2024
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Epilepsy
- NCT number
- NCT06028945
What you commit to
- Study type: Interventional
- Participants enrolled: 14
- From 24 May 2024 to the primary completion date, 11 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals who have started an antidepressant, antianxiety drug, or medical marijuana in the last twelve weeks
Other illness
- Individuals with an unconfirmed epilepsy diagnosis
- Individuals with photosensitive epilepsy
- Individuals with open wounds on the face or cervical conditions or injuries that would make it unsafe for use the VR headset
Other
- Individuals with stereotaxic EEG monitoring
- Individuals who cannot speak or understand English
Who the study is looking for
- Individuals who are at least 18 years old
- Individuals admitted to the EMU
- Individuals who have self-reported anxiety related to having epilepsy or seizures
- Individuals who score \<15 on the Fast Motion Sickness (FMS) after the VR neutral demo
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Toronto Western Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.